Biohaven Ltd (NYSE:BHVN)
$ 38.72 -0.6 (-1.53%) Market Cap: 3.42 Bil Enterprise Value: 3.22 Bil PE Ratio: 0 PB Ratio: 10.67 GF Score: 21/100

Biohaven Pharmaceutical Holding Company Ltd Investor Update Transcript

Feb 28, 2020 / 01:00PM GMT
Operator

Greetings, and welcome to the Biohaven Nurtec conference call. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to introduce your host, Kim Gentile. Please go ahead.

Kimberly Gentile

Great. Thank you very much, and welcome to the Biohaven conference call to discuss the FDA approval of Nurtec ODT, rimegepant, orally disintegrating tablet. I'm Kim Gentile, Senior Vice President of Clinical Operations.

Speaking on today's call are Dr. Vlad Coric, our Chief Executive Officer; Dr. Elyse Stock, our Chief Medical Officer; Dr. Robert Croop, our Chief Development Officer of Neurology; and BJ Jones, our Chief Commercial Officer of Migraine and Common Diseases.

For the Q&A portion, we will be joined by Dr. Charles Conway, our Chief Scientific Officer; and Jim Engelhart, our Chief Financial Officer. Yesterday, we issued a press release announcing the FDA's approval of Nurtec ODT, an oral small molecule CGRP receptor antagonist for the acute treatment of migraine with or without or in adults. A copy of this press

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot